文献速递前列腺癌

可见病灶男性中系统与靶向MRI/US融合前列腺穿刺的比较

Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
PubMed 文献 · J Urol · 2021-08-24

该研究纳入1236例有可见PI-RADS v2病灶的男性,比较系统、靶向及联合穿刺对前列腺癌的检出。联合穿刺检出33.3%的临床显著前列腺癌(csPCa),靶向穿刺较系统穿刺csPCa检出率提高4.6%但GG1前列腺癌减少6.5%。联合穿刺较系统穿刺csPCa检出率提高10.0%且GG1前列腺癌略减少0.5%。

要点

  • 联合穿刺较系统穿刺csPCa检出率提高10.0%,GG1前列腺癌略减少0.5%。
  • 靶向穿刺较系统穿刺csPCa检出率提高4.6%,GG1前列腺癌减少6.5%。
  • 靶向穿刺的csPCa获益在既往阴性活检者中更高(+7.8% vs +1.7%)。

核心结论

  • 联合穿刺在csPCa检出上的获益是靶向穿刺单用的两倍,且不增加GG1前列腺癌诊断。
  • 靶向穿刺的效用在于既往阴性活检队列更高,但联合穿刺的优势不受活检史影响。

研究设计与样本

  • 多中心回顾性研究,纳入2015-2020年2家机构临床怀疑前列腺癌且PI-RADS v2可见病灶的男性,共1236例(647例首次活检)。
  • 所有患者接受mpMRI-US融合引导前列腺穿刺,比较系统、靶向及联合穿刺的检出率。

主要发现

  • 联合穿刺检出前列腺癌626例(50.6%),csPCa 412例(33.3%)。
  • 靶向穿刺较系统穿刺csPCa检出率提高4.6%(27.9% vs 23.3%),GG1前列腺癌减少6.5%(11.3% vs 17.8%)。
  • 靶向穿刺的csPCa获益在既往阴性活检者中为+7.8%(p<0.0001),首次活检者为+1.7%(p=0.3)。
  • 联合穿刺较系统穿刺csPCa检出率提高10.0%,GG1前列腺癌减少0.5%。
  • 靶向穿刺使系统穿刺无癌者中9.8%升级为≥GG2,系统穿刺GG1者中23.6%升级为≥GG2。

关键数值与推荐

  • csPCa定义为≥GG2。
  • 靶向穿刺对PI-RADS 5病灶csPCa检出增加,对PI-RADS 3病灶GG1减少,对PI-RADS 4病灶两者均有。
  • 靶向穿刺csPCa获益在既往阴性活检者中+7.8%(p<0.0001),首次活检者+1.7%(p=0.3)。

临床怎么用

  • 联合穿刺应作为可见病灶男性的首选策略,以最大化csPCa检出并减少GG1诊断。
  • 既往阴性活检者可从靶向穿刺中获得更高的csPCa检出获益。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 仅纳入PI-RADS v2可见病灶患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiparametric magnetic resonance imaging (mpMRI)-ultrasound (US) fusion-guided biopsy may improve prostate cancer (PCa) detection and reduce grade misclassification. We compared PCa detection rates on systematic, magnetic resonance imaging-targeted, and combined biopsy with evaluation of important subgroups. MATERIALS AND METHODS: Men with clinical suspicion of harboring PCa from 2 institutions with visible Prostate Imaging-Reporting and Data System (PI-RADSTMv2) lesions receiving mpMRI-US fusion-guided prostate biopsy were included (2015-2020). Detection of PCa was categorized by grade group (GG). Clinically-significant PCa (csPCa) was defined as ≥GG2. Patients were stratified by biopsy setting and PI-RADS. RESULTS: Of 1,236 patients (647 biopsy-naïve) included, 626 (50.6%) harbored PCa and 412 (33.3%) had csPCa on combined biopsy. Detection of csPCa was 27.9% vs 23.3% (+4.6%) and GG1 PCa was 11.3% vs 17.8% (-6.5%) for targeted vs systematic cores. Benefit in csPCa detection was higher in the prior negative than biopsy-naïve setting (+7.8% [p <0.0001] vs +1.7% [p=0.3]) while reduction in GG1 PCa detection remained similar (-5.6% [p=0.0002] vs -7.3% [p=0.0001]). Targeted biopsy showed increased csPCa detection for PI-RADS 5, decrease in GG1 for PI-RADS 3, and both for PI-RADS 4 relative to systematic biopsy. Combined biopsy detected more csPCa (+10.0%) and slightly fewer GG1 PCa (-0.5%) compared to systematic alone. Upgrading to ≥GG2 by targeted biopsy occurred in 9.8% with no cancer and 23.6% with GG1 on systematic biopsy. CONCLUSIONS: Combined biopsy doubled the benefit of targeted biopsy alone in detection of csPCa without increasing GG1 PCa diagnoses relative to systematic biopsy. Utility of targeted biopsy was higher in the prior negative biopsy cohort, but advantages of combined biopsy were maintained regardless of biopsy history.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Patel HD, Koehne EL, Shea SM, et al. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions. J Urol. 2021. PMID: 34428091. doi:10.1097/JU.0000000000002120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。